Benitec Biopharma Ltd ADR BNTC

$8.11 -0.35 (-4.14%)

Valuation

Market cap
282,901,000
Revenue TTM
$0
Net income TTM
$-45,550,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
158,500
Avg volume
183,980
Day's range
$8.06 – $8.47
Shares out
34,883,000
Stochastic %K
3%
Beta
0.25
Analysts
Strong Sell
Price target
$24.33

Price

Company profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a s...

Show more

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Industry
Biotechnology
Sector
Healthcare
Phone
510 780 0819
Website
https://benitec.com
Address
3940 Trust Way, Hayward, United States

Latest news

Stocktwits

buymoremakemore Oct 14, 11:06 PM
$BNTC 52 week low today. Way oversold. Down from nearly $15 earlier this year on no news. Promising readout in 2 weeks. Pivotal data likely in less than a year that can lead to accelerated approval. Lots of cash to get there.
1 replies
RTPRwire Oct 5, 4:48 PM
$BNTC is seeing a strong reaction on clinical trial results following a Globe Newswire release. Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study RTPR pushed this release out to users at 8:00:01 AM ET
0 replies
OpenOutcrier Oct 5, 12:35 PM
$BNTC (-0.7% pre) Benitec gets FDA feedback on BB-301 pivotal study design https://ooc.bz/l/116507
0 replies
focafoca99 Sep 24, 9:06 PM
$BNTC changed its independent auditor, dismissing Baker Tilly and appointing EY as the new audit firm.
0 replies
d_risk Sep 14, 8:32 PM
$BNTC - Benitec Biopharma Inc - 10K - Updated Risk Factors BNTC flags continued heavy losses, no product revenue, dependence on new capital to remain a going concern, early-stage unproven ddRNAi gene therapy facing tougher FDA demands and trial hurdles, heavy reliance on third parties and IP protection, uncertain physician/payer uptake, and added risks from U.S. government funding and FDA staffing disruptions. #Biopharmaceuticals #GeneTherapy #RegulatoryRisk #CapitalDependency #IntellectualProperty 🟢 Added 🟠 Removed https://d-risk.ai/BNTC/10-K/2026-09-14
0 replies
SuperGreenToday Jun 10, 8:31 PM
$BNTC Share Price: $10.40 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.71 – $0.87 Potential Upside: 57% ROI Time to Expiration: 127 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
focafoca99 May 14, 12:32 PM
$BNTC released its fiscal quarter ended March 31, 2026 results and operational update.
0 replies
OpenOutcrier Apr 28, 12:34 PM
$BNTC (+2.2% pre) Benitec Biopharma to present BB-301 clinical data at gene therapy meeting https://ooc.bz/l/100204
0 replies